| Dry Eye Syndromes
Eysuvis vs Lacrisert
Side-by-side clinical, coverage, and cost comparison for dry eye syndromes.Deep comparison between: Eysuvis vs Lacrisert with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLacrisert has a higher rate of injection site reactions vs Eysuvis based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lacrisert but not Eysuvis, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Eysuvis
Lacrisert
At A Glance
Ophthalmic
Four times daily
Corticosteroid
Ophthalmic insert
Once daily
Ocular lubricant
Indications
- Dry Eye Syndromes
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- Exposure keratoconjunctivitis
- Corneal hypoesthesia
- Recurrent erosion of cornea
Dosing
Dry Eye Syndromes Instill one to two drops into each eye four times daily for up to two weeks.
Dry Eye Syndromes, Keratoconjunctivitis Sicca, Exposure keratoconjunctivitis, Corneal hypoesthesia, Recurrent erosion of cornea One ophthalmic insert in each eye once daily; some patients may require twice daily use for optimal results; insert into the inferior cul-de-sac of the eye beneath the base of the tarsus.
Contraindications
- Most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella
- Mycobacterial infection of the eye
- Fungal diseases of ocular structures
- Hypersensitivity to hydroxypropyl cellulose
Adverse Reactions
Most common (>=5%) Instillation site pain
Serious Elevated intraocular pressure, optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, delayed wound healing, secondary ocular infection from pathogens including herpes simplex, perforation of the globe
Most common Transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, edema of the eyelids, hyperemia
Pharmacology
Corticosteroid that inhibits the inflammatory response by suppressing edema, fibrin deposition, capillary dilation, leukocyte migration, fibroblast proliferation, and collagen deposition, likely via inhibition of prostaglandin production through glucocorticoid receptor binding.
Ocular lubricant; stabilizes and thickens the precorneal tear film and prolongs tear film breakup time to reduce signs and symptoms of dry eye syndromes, including lubrication and protection of the eye.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Eysuvis
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (10/12)
Lacrisert
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Eysuvis
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Lacrisert
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Eysuvis
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (2/3)
Lacrisert
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Eysuvis.
No savings programs available for Lacrisert.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EysuvisView full Eysuvis profile
LacrisertView full Lacrisert profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.